# Extended-Release RANCAD in the Patients With Stable Angina Pectoris

> **NCT02294942** · PHASE3 · COMPLETED · sponsor: **TSH Biopharm Corporation Limited** · enrollment: 75 (actual)

## Conditions studied

- Stable Angina Pectoris

## Interventions

- **DRUG:** RANCAD

## Key facts

- **NCT ID:** NCT02294942
- **Lead sponsor:** TSH Biopharm Corporation Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2017-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02294942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02294942, "Extended-Release RANCAD in the Patients With Stable Angina Pectoris". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02294942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*